Low-Dose Brachytherapy Improves Disease-Free Survival in Unfavorable-Risk Prostate Cancer

Share this content:
Low-dose-rate brachytherapy boost achieves better rates of biochemically disease-free outcomes.
Low-dose-rate brachytherapy boost achieves better rates of biochemically disease-free outcomes.

ORLANDO—Compared to dose-escalated external beam radiotherapy (DE-EBRT), iodine-125 low-dose-rate brachytherapy boost (LDR-PB) achieves better rates of biochemically disease-free outcomes, but not superior overall survival, for men with intermediate- and high-risk localized prostate cancer, according to findings from the multicenter randomized ASCENDE-RT study (Abstract 3), presented during the 2015 Genitourinary Cancers Symposium.1

“In the context of 12 months of ADT and whole pelvis radiation therapy, treatment with LDR-PB boost results in a 50% reduction in biochemical relapse compared to DE-EBRT to 78 Gy,” reported Scott Tyldesley, MD, of the BC Cancer Agency in Vancouver, British Columbia, Canada. “The absolute difference in biochemical disease-free survival at 7 years was approximately 11%.”

At 6.5 years follow-up, there was no difference in overall survival (OS), prostate cancer-specific survival, or metastasis-free survival, Dr. Tyldesley said.

LDR-PB was associated with higher rates of late grade 3 or higher genitourinary toxicity according to Dr. Tyldesley.

A total of 398 men with intermediate- (276 patients) or high-risk (122 patients) localized prostate cancer were enrolled during December 2002 through September 2011 and randomly assigned to receive either external beam radiotherapy (DE-EBERT, standard treatment arm: 200 patients) or LDR-PB (198 patients).

All participants received 12 months of androgen deprivation therapy (ADT) with luteinizing hormone releasing hormone (LHRH) agonist plus a nonsteroidal antiandrogen for at least 1 month.

After 8 months of neo-adjuvant ADT, patients in both study arms received whole-pelvis EBRT (46 Gy in 23 fractions) before being receiving either a conformal EBRT boost (32 Gy) or an iodine-125 LDR boost prescribed to a minimum peripheral dose of 115 Gy.

The primary study endpoint was relapse-free survival (RFS) determined by biochemical criteria using the nadir+2 ng/mL threshold, calculated from the date of first LHRH agonist injection.

There were 29 (7%) major protocol violations, including 14 cross-over events in which patients opted to leave their assigned study arm and receive the other treatment, and 15 men who received neither regimen.

RELATED: Brachytherapy: An Underused Option for Prostate Cancer?

Intent-to-treat analysis showed that patients in the LDR-PB study arm saw a significantly longer biochemical progression-free survival (9-year PFS: 62.4 months vs. 83.3 months; P=0.001).

PFS for patients in the NCCN intermediate-risk group (122 patients) saw a greater benefit from LDR-PB (9-year PFS: 93.9 months vs. 69.8 months; P<0.001) than patients in the high-risk group (276 patients; 9-year PFS: 78 vs. 58.2 months; P=0.05). Factors predictive of RFS in a multivariate analysis included randomization (P=0.004), percent positive cores (P=0.006), initial PSA (P=0.01), and clinical T-stage (P=0.004).

By the fifth year of follow-up, LDR-PB was associated with significantly more late grade 3 genitourinary (GU) toxicities (5-year cumulative incidence of G3 toxicity: 19% LDR-PB vs. 5% for DE-EBRT; P<0.001), Dr. Tyldesley reported. This translated to an approximate 5% to 6% increase in long-term prevalence, he said. Half of late grade 3 or higher GU toxicities in the LDR-PB arm were urethral strictures.

Reference

  1. Morris WJ, Tyldesley S, Pai HH, et al. ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer. 2015 Genitourinary Cancers Symposium. Abstract 3.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters